Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
PAC203: Pacritinib Dose-Finding Study in Myelofibrosis Post-Ruxolitinib
NCT04884191Phase 2Completed
- Sponsor
- CTI BioPharma Corp.
- Start
- Jul 2017
- Primary completion
- Sep 2019
- Modality
- Small Molecules
- Countries
- 8
01
Overview
A Phase 2 trial of pacritinib in primary myelofibrosis (PMF), post-polycythemia vera myelofibrosis (PPV-MF), post-essential thrombocythemia myelofibrosis (PET-MF), sponsored by CTI BioPharma Corp.. Started Jul 2017; status: completed.
02
Drugs
pacritinib
03
Conditions
primary myelofibrosis (PMF)post-polycythemia vera myelofibrosis (PPV-MF)post-essential thrombocythemia myelofibrosis (PET-MF)
Beyond the preview
Go deeper on NCT04884191.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04884191.